We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trefoil Peptides in Lung Diseases

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Bispebjerg Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00839735
First Posted: February 9, 2009
Last Update Posted: February 9, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
  Purpose
The study focuses on trefoil family factor (TFF) peptides in sputum in lung diseases. The investigators hypothesize that TFF peptides are upregulated in lung diseases characterized by mucus hypersecretion.

Condition
Chronic Obstructive Pulmonary Disease Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Trefoil Peptides in Lung Diseases

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Primary Outcome Measures:
  • TFF in sputum [ Time Frame: Monthly ]

Estimated Enrollment: 60
Study Start Date: February 2009
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
COPD
Chronic obstructive pulmonary disease
Asthma
Healthy controls

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Subjects with chronic obstruction pulmonary disease (COPD) Subjects with asthma Healthy volunteers
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Informed consent

Exclusion Criteria:

  • Upper and lower airway infection 2 weeks prior to visit 1
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00839735


Contacts
Contact: Thomas K Lund, MD PhD (+45) 35 31 30 69 tclund@dadlnet.dk
Contact: Lars Pedersen, MD PhD (+45) 35 31 30 69 lars.pedersen@dadlnet.dk

Locations
Denmark
Respiratory and Allergy Research Unit, Department of Respiratory Medicine L, Bispebjerg Hospital Recruiting
Copenhagen, Denmark, 2400
Contact: Thomas K Lund, MD PhD    (+45) 35 31 30 69    tclund@dadlnet.dk   
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Principal Investigator: Thomas K Lund, MD PhD Respiratory and Allergy Research Unit
  More Information

Responsible Party: Thomas K. Lund (MD PhD) & Lars Pedersen (MD PhD), Respiratory and Allergy Research Unit, Department of Respiratory Medicine, Bispebjerg Hospital, Copenhagen, Denmark
ClinicalTrials.gov Identifier: NCT00839735     History of Changes
Other Study ID Numbers: H-B-2008-120
First Submitted: February 6, 2009
First Posted: February 9, 2009
Last Update Posted: February 9, 2009
Last Verified: February 2009

Keywords provided by Bispebjerg Hospital:
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases